<DOC>
	<DOCNO>NCT02759042</DOCNO>
	<brief_summary>The primary objective provide continue access PRO 140 subject complete participation PRO140_CD02 .</brief_summary>
	<brief_title>An Expanded Access Protocol Single Subject Who Has Completed 24-Weeks Treatment PR0140_CD02 Study</brief_title>
	<detailed_description>This open label , single center study design provide continued access PRO 140 subject complete participation PRO140_CD02 continue receive clinical benefit . The subject receive weekly PRO 140 SC injection along oral ART regimen Treatment Phase . The study treatment ( PRO 140 SC injection ) administer qualified medical professional self-administered subject .</detailed_description>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>HIV Antibodies</mesh_term>
	<mesh_term>PRO-140 monoclonal antibody</mesh_term>
	<criteria>This study recruit one treatmentexperienced , HIV1 infect patient CCR5tropic virus , participate PRO 140_CD02 clinical trial continue derive clinical benefit PRO 140 treatment .</criteria>
	<gender>Male</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>56 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>